Moberg Pharma AB (publ) Total Liabilities
Moberg Pharma AB (publ) total liabilities. Based on the latest financial reports, Moberg Pharma AB (publ) (MOB) has total liabilities worth Skr17.04 Million SEK (≈ $1.83 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Moberg Pharma AB (publ) to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Moberg Pharma AB (publ) (2008–2025)
Total liabilities of Moberg Pharma AB (publ) from 2008 to 2025. This chart illustrates how Moberg Pharma AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore Moberg Pharma AB (publ) long-term investment intensity to see how much of total assets are deployed in long-term investments.
Moberg Pharma AB (publ) Competitors by Total Liabilities
The table below lists competitors of Moberg Pharma AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
W S Industries (I) Limited
NSE:WSI
|
India | Rs-3.95 Billion |
|
Titania Holding AB Series B
ST:TITA-B
|
Sweden | Skr4.41 Billion |
|
TECO Image Systems Co Ltd
TWO:5438
|
Taiwan | NT$780.96 Million |
|
Marpai Inc
NASDAQ:MRAI
|
USA | $46.16 Million |
|
POBIS TNC CO. Ltd
KQ:016670
|
Korea | ₩55.88 Billion |
|
New Hoong Fatt Holdings Bhd
KLSE:7060
|
Malaysia | RM63.21 Million |
|
Global View Co Ltd
TW:3040
|
Taiwan | NT$574.45 Million |
|
Global Self Storage Inc
NASDAQ:SELF
|
USA | $17.32 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Moberg Pharma AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Moberg Pharma AB (publ).
Liquidity & Leverage Metrics
Moberg Pharma AB (publ) Total Liabilities Ratios Explained
Moberg Pharma AB (publ) total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.75 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Moberg Pharma AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Moberg Pharma AB (publ) (2008–2025)
The table below shows the annual total liabilities of Moberg Pharma AB (publ) from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr17.04 Million ≈ $1.83 Million |
-11.55% |
| 2024-12-31 | Skr19.27 Million ≈ $2.07 Million |
-19.73% |
| 2023-12-31 | Skr24.01 Million ≈ $2.58 Million |
-22.15% |
| 2022-12-31 | Skr30.84 Million ≈ $3.32 Million |
+83.15% |
| 2021-12-31 | Skr16.84 Million ≈ $1.81 Million |
-80.19% |
| 2020-12-31 | Skr85.00 Million ≈ $9.15 Million |
+241.22% |
| 2019-12-31 | Skr24.91 Million ≈ $2.68 Million |
-96.21% |
| 2018-12-31 | Skr657.60 Million ≈ $70.77 Million |
-1.98% |
| 2017-12-31 | Skr670.85 Million ≈ $72.19 Million |
+0.04% |
| 2016-12-31 | Skr670.55 Million ≈ $72.16 Million |
+1402.43% |
| 2015-12-31 | Skr44.63 Million ≈ $4.80 Million |
-20.26% |
| 2014-12-31 | Skr55.97 Million ≈ $6.02 Million |
-20.17% |
| 2013-12-31 | Skr70.11 Million ≈ $7.55 Million |
-31.61% |
| 2012-12-31 | Skr102.53 Million ≈ $11.03 Million |
+554.46% |
| 2011-12-31 | Skr15.67 Million ≈ $1.69 Million |
+33.96% |
| 2010-12-31 | Skr11.69 Million ≈ $1.26 Million |
+129.85% |
| 2009-12-31 | Skr5.09 Million ≈ $547.55K |
-30.83% |
| 2008-12-31 | Skr7.36 Million ≈ $791.64K |
-- |
About Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.